RxDoctor Payments Data

Robert Carlson, MD

Family Medicine · Hastings, MINPI 1396856910

Payments from drug & device makers

$7,969in general payments, 2019–2025

Across 449 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$771
  • Astellas Pharma US Inc$667
  • Novo Nordisk$595
  • Boehringer Ingelheim$591
  • Pfizer$563
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,74097%
  • Education$2283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,969 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$142,047
Medicare patients
250
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$110,416
FarxigaDapagliflozin Propanediol95$101,138
JardianceEmpagliflozin68$80,551
JanuviaSitagliptin Phosphate69$59,869
XareltoRivaroxaban29$41,440
TrulicityDulaglutide21$35,096
JanumetSitagliptin Phos/Metformin Hcl31$32,483
OzempicSemaglutide13$27,169
MyrbetriqMirabegron45$26,898
MounjaroTirzepatide14$24,850
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$21,546
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,714
Nurtec OdtRimegepant Sulfate14$13,674
Budesonide ErBudesonide11$12,191
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$11,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,106$129,534141 claims
PfizerEliquis, Nurtec Odt$563$124,089146 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Trijardy Xr$591$99,05697 claims
MerckJanuvia, Janumet$147$92,351100 claims
Lilly USA, LLCTrulicity, Mounjaro$377$59,94735 claims
Johnson & JohnsonXarelto, Invokana$182$48,19541 claims
Novo NordiskOzempic$595$27,16913 claims
Astellas Pharma US IncMyrbetriq$667$26,89845 claims
GSKTrelegy Ellipta, Shingrix$229$23,57943 claims
AbbVieArmour Thyroid$771$2,88215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Hastings

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →